Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$277 Mln
P/E Ratio
--
P/B Ratio
1.78
Industry P/E
--
Debt to Equity
0.12
ROE
-0.46 %
ROCE
-41.77 %
Div. Yield
0 %
Book Value
3.04
EPS
-1.74
CFO
$-195.85 Mln
EBITDA
$-223.91 Mln
Net Profit
$-214.47 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aura Biosciences Inc (AURA)
| -34.55 | -23.14 | -31.81 | -24.23 | -31.69 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Aura Biosciences Inc (AURA)
| -7.17 | -15.62 | -38.16 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles... conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts. Read more
Founder, CEO, President & Director
Dr. Elisabet de los Pinos Ph.D.
Founder, CEO, President & Director
Dr. Elisabet de los Pinos Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aura Biosciences Inc (AURA) stood at $ 183 Mln as on 31-Dec-24
The share price of Aura Biosciences Inc (AURA) is $5.38 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Aura Biosciences Inc (AURA) has given a return of -31.69% in the last 3 years.
Aura Biosciences Inc (AURA) has a market capitalisation of $ 277 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Aura Biosciences Inc (AURA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aura Biosciences Inc (AURA) and enter the required number of quantities and click on buy to purchase the shares of Aura Biosciences Inc (AURA).
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts.
The CEO & director of Dr. Elisabet de los Pinos Ph.D.. is Aura Biosciences Inc (AURA), and CFO & Sr. VP is Dr. Elisabet de los Pinos Ph.D..
There is no promoter pledging in Aura Biosciences Inc (AURA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Aura Biosciences Inc (AURA) | Ratios |
|---|---|
|
Return on equity(%)
|
-46.01
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aura Biosciences Inc (AURA) was $0 Mln.
$-0.14
(
